A new approach to Huntington’s disease?
At the 2014 AAN Annual Meeting, investigators reported the results of a double-blind, placebo-controlled, international multi-center study of selisistat in individuals with Huntington’s disease (HD). They found that, apart from increases in liver function tests in a subset of patients, selisistat was safe and well tolerated. In this video, Neurology Today Editor-in-chief Steven P. Ringel, MD, and Neurology Today Associate Editor Robert G. Holloway Jr., MD, MPH, discuss the meaning of these results with David Holtzman, MD, professor and chair of neurology at Washington University in St. Louis. See the full meeting abstract here: http://bit.ly/HD-neuro.